[Press Release] SK bioscience has once again demonstrated its leadership in ESG management within Korea’s pharmaceutical and biotechnology sector.

The company announced on the 19th that it received an integrated A rating in the 2025 ESG assessment conducted by the Korea Institute of Corporate Governance and Sustainability (KCGS). SK bioscience has maintained the same grade for four consecutive years since it first earned an A rating in 2022, underscoring the company’s recognized capabilities and strong standing in sustainable management.

The KCGS ESG assessment is regarded as one of the most credible ESG evaluations in Korea, comprehensively reviewing the policies, management systems, performance, and disclosure standards of major listed companies across the pillars of Environmental, Social, and Governance. SK bioscience received high marks for its continued enhancement of systematic management and transparent information disclosure across all three areas.

To execute ESG management at a global level, SK bioscience has established a company-wide governance structure. The Board of Directors operates an ESG Committee that deliberates and approves key policies and strategies, while a dedicated ESG team strengthens execution and performance management across business units. The company has also published an annual ESG report since 2022 based on GRI Standards (2021) to improve transparency and reliability in ESG disclosures.

In the environmental domain, SK bioscience has set clear reduction targets for major indicators such as pollutant emissions, water use, and waste generation, while operating a transparent system to disclose progress against these goals. The company continues to expand resource-efficiency and environmental-impact reduction initiatives, including eco-friendly process improvements and energy-saving efforts centered on its Andong L HOUSE manufacturing facility.

In the social domain, SK bioscience has strengthened its human rights management policy and advanced a systematic process to identify and manage key human rights risks. The company provides enhanced human rights and ethics training for employees and partners, while monitoring human rights risks throughout its supply chain. Through activities spanning occupational safety, community engagement, and social contribution, SK bioscience continues to reinforce its role as a company that contributes to a healthier society.

In the governance domain, SK bioscience has institutionalized board-level training, strengthened the expertise of its Audit Committee, improved procedures for shareholder meeting notices, and expanded disclosures in its business reports?efforts that enhance transparency with shareholders and stakeholders. The company has also clarified the roles and authority of board committees and reinforced their independence to ensure responsible decision-making.

"ESG is more than a scoring metric?it is a core strategic pillar that drives the company's sustainable growth," said Jong Soo Park, Head of Sustainability at SK bioscience. "We will continue to advance our management systems to global standards across all environmental, social, and governance areas."

SK bioscience continues to maintain A-level ratings or higher from major domestic and global ESG evaluators, including KCGS and MSCI, positioning the company among the leading performers in Korea’s pharmaceutical and biotech industry. Going forward, SK bioscience plans to further strengthen its globally aligned ESG management system and build a virtuous cycle that enhances both environmental and social value as well as corporate competitiveness, reinforcing sustainable growth and public trust.